Following submission on June 16, the NDA was accepted for review as a “complete class 2 response” by the FDA on July 16, 2025, with a target PDUFA action date of December 16. Also Read: FDA Rejects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback